MedPath

Application of Needle-free Injection of Insulin in Patients With Gestational Diabetes Mellitus

Not Applicable
Recruiting
Conditions
Blood Glucose, High
Injection
Glycemic Control
Gestational Diabetes
Interventions
Device: Needle-free injection device, Then traditional insulin pen
Device: Traditional insulin pen , Then Needle-free injection device
Registration Number
NCT05394727
Lead Sponsor
Nanfang Hospital, Southern Medical University
Brief Summary

This study is about the application of needle-free injection device in GDM patients in order to observe the variation of blood glucose and patients' experience compared to the traditional insulin pen injection. To provide evidence for the application of needle-free syringe injection in GDM patients.

Detailed Description

This study is a prospective, randomized, unblinded,crossover and controlled clinical trail. The first patient was enrolled on November 1, 2019. The follow-up visit of all enrolled patients in our center will be finished on June 30, 2021. There are two arms in our study : Test Group(IG,n=20) and Control Group(CG,n=20), 40 patients totally.

Test group: "Needle-free injection device, Then traditional insulin pen" Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.

Control group: "Traditional insulin pen , Then Needle-free injection device" Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • Patients'diagnostic criteria of gestational diabetes mellitus(GDM) is according to the Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition).
  • fasting glucose or 2h post prandial glucose was abnormal after 3days' dietary control (fasting glucose ≥ 6.1 mmol/L, or 2h post prandial glucose ≥7.8 mmol/L).
  • Aged≥20 years, Han, singleton pregnancy.
  • Patients who gave informed consent voluntarily participated in the study, and had regular perinatal examination at our hospital and intended to deliver at our hospital.
Exclusion Criteria
  • Patients with multiple pregnancy or undergoing assisted reproductive technology.
  • Patients with polycystic ovary syndrome in preconception.
  • Patients with other endocrine metabolic disorders such as gestational hypertension and hyperthyroidism.
  • Patients with severe anemia and hypoproteinemia, abnormal liver and kidney function, severe heart failure, respiratory failure and other systemic diseases.
  • Patients on long-term medications that affect glucose metabolism.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Needle-free injection first groupNeedle-free injection device, Then traditional insulin penUse needle-free syringe for insulin injection in patients for 2 weeks, then replace it with conventional insulin pen injection for another 2 weeks.
Traditional insulin pen first groupTraditional insulin pen , Then Needle-free injection deviceUse conventional insulin pen for insulin injection in patients for 2 weeks, then replace it with needle-free syringe injection for another 2 weeks.
Primary Outcome Measures
NameTimeMethod
Change from baseline in Blood Glucose Indicators to week 4Baseline, week 2, week 4

The blood glucose indicators include fasting blood glucose and blood glucose of 0.5,1,2,3 hours post-meals. Change=(Week 4 blood glucose indicators - Week 2 blood glucose indicators - Baseline blood glucose indicators).

Change from baseline in Plasma insulin concentrations to week 4Baseline, week 2, week 4

The Plasma insulin concentrations include fasting plasma insulin concentration and plasma insulin concentrations of 0.5,1,2,3 hours post-meals. Change=(Week 4 plasma insulin concentrations - Week 2 plasma insulin concentrations - Baseline plasma insulin concentrations).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Nanfang Hospital, southern medical university

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath